Business Wire

Alisher Usmanov Wins Legal Case Against Luxembourg’s Largest Media Group, Says Law Firm Rechtsanwälte Steinhöfel

Share

A German court has banned Mediahuis Luxembourg S.A., the most important media holding in Luxembourg, from referring to Alisher Usmanov as the owner of the yacht Dilbar.

Mediahuis Luxembourg is the leading publishing company in Luxembourg, with such assets as newspapers and online platforms, including Luxemburger Wort, Luxembourg Times and others. On May 5, 2025, the Regional Court of Hamburg ruled that the following statement published by Luxembourg Times was false and prohibited its further publication: “The luxury yacht Dilbar was seized in Hamburg’s harbour in 2022 following Russia’s invasion under EU sanctions. The yacht is owned through a company and trust by Uzbek-Russian billionaire Alisher Usmanov.”

The court found the statement to be in violation of Mr. Usmanov’s rights and prohibited its distribution.

In the event of non-compliance with the prohibition, Mediahuis may be fined up to €250,000 for each individual offense. Moreover, if such a fine is not enforceable, it may be replaced with an administrative detention of up to six months per offense, with a maximum of two years in total.

The disputed paragraph from the article has been removed from the Luxembourg Times website.

Since 2023, Mr. Usmanov’s legal counsels have obtained 10 court rulings and injunctions against media outlets that were attributing property in the Federal Republic of Germany and other various assets in the country to Mr. Usmanov. In reality, these properties and assets are held in irrevocable trusts and belong to their managers – independent trustees. In addition, some 40 cease-and-desist letters have been served, resulting in hundreds of media outlets withdrawing or correcting their articles.

Joachim Steinhöfel, a lawyer specializing in press law and representing Mr. Usmanov, said: “Media outlets have persistently and unlawfully alleged that Mr. Usmanov uses family members, shell companies, or trusts to conceal ownership of some assets — claims that are demonstrably false. Long before the ruling on Luxembourg Times, we obtained multiple court injunctions and cease-and-desist declarations prohibiting such defamatory assertions or promises to cease and desist, which were secured by contractual penalties.

Despite their legal invalidity and subsequent removal or correction, such articles have nonetheless been cited in investigative files and EU sanctions documents targeting our client.

The fact that prosecutorial authorities and EU sanctioning bodies rely on discredited and judicially banned media content raises serious concerns of procedural impropriety. It constitutes a clear abuse of discretion and a potential violation of due process rights. Decisions derived from such flawed sources lack both legal and moral legitimacy.”

On the defamation cases brought by Alisher Usmanov and Gulbakhor Ismailova

Between 2023 and 2025, a number of European, mainly German, media outlets and public figures acknowledged their inability to prove their allegations against Alisher Usmanov and his sister, Gulbakhor Ismailova, and subsequently undertook in writing to cease their illegal distribution.

One of the most noteworthy is the ruling in January 2024 prohibiting several claims made by the U.S. magazine Forbes against Mr. Usmanov that were used to justify the imposition of the EU sanctions on him. Usmanov has also won legal battles against many other outlets, including the German newspaper Tagesspiegel, Austria’s Kurier, and major German television and radio channels RTL and ARD/Westdeutscher Rundfunk.

In April 2025, the German newspaper Münchner Merkur took down 15 articles on Alisher Usmanov and Gulbakhor Ismailova at once. Some of these articles had been used to trigger investigations into Mr. Usmanov in Germany, and their content was later included in the EU’s sanctions dossiers against both Mr. Usmanov and Ms. Ismailova.

In February 2025, Germany’s leading news agency, dpa, informed its partners in the FRG and international media partners of the retraction of its April 13, 2022, article claiming that Ms. Ismailova was presumably the owner of the yacht Dilbar, citing the retraction by the Federal Criminal Police Office (BKA) of its April 2022 statement on the X platform (formerly Twitter). (The BKA deleted the original post after receiving a cease-and-desist letter from Mr. Usmanov’s legal counsel and confirmed that it would no longer propagate it.) Dpa also advised them to withdraw the publication “to avoid any legal dispute.” The article in question disappeared from the websites of numerous media, such Frankfurter Allgemeine Zeitung, Süddeutsche Zeitung, Zeit, Neue Osnabrücker Zeitung and others.

In March 2025, Tagesschau, Germany’s longest-running and most-watched television news program, was also forced to remove similar content from its website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250512172984/en/

Contacts

Alisher Usmanov’s Press Service
pressoffice@usm-group.com

Joachim Nikolaus Steinhöfel, attorney
ABC-Str. 38, 20354 Hamburg
mail@steinhoefel.de – Tel.: +49 40 444599

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study

Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press Release

Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly

Traxys Group and the Shareholders of Comax2 AB - the holding company of Carbomax AB - sign Share Purchase Agreement to sell 100% interests to Traxys Group12.1.2026 19:20:00 CET | Press Release

Traxys S.à.r.l., Investment Aktiebolaget Spiltan and other major shareholders of Comax 2 AB – the holding company of Carbomax AB –are pleased to announce that they have signed a Share Purchase Agreement (SPA) to sell 100% interests to Traxys Group. Carbomax AB is a leading Swedish trading house and industrial operator specializing in ferroalloys, carbon products and briquettes. The transaction aims to strengthen Traxys’ presence in the Scandinavian market and support the region’s transition toward sustainable steel production. Closing of the transaction is expected to occur in the first quarter 2026 following clearance by Swedish authorities, including foreign direct investment and antitrust approvals. Carbomax serves regional steel plants and most of foundries across the Nordics. With its strategic location near Västerås harbor and integrated processing capabilities Carbomax is well-positioned to capitalize on growing demand for green steel and sustainable raw materials. Mark Kristoff

Lenovo Brings Real-Time Store Visibility and AI-Driven Support to Retail—Delivering Value on Day One12.1.2026 19:00:00 CET | Press Release

Retailers lose revenue every time an online store goes down, a system fails, or frontline employees lack the tools to act in the moment. Meanwhile, generative AI platforms and AI agents are creating new opportunities to increase online retail experiences and conversion rates. Yet while AI has the potential to help retailers drive better margins and competitive advantage, many still find it challenging to translate experimentation into consistent, day-to-day operational and revenue improvements. Today at NRF: Retail’s Big Show, Lenovo announced their latest AI-powered solutions - Smart Store Services and AI Retail Assistants - designed to deliver immediate, measurable value for retailers. Supported by Lenovo Hybrid AI Services, the solutions embed AI directly into daily retail operations, helping retailers prevent disruptions before revenue is lost, support associates in real time, and scale AI into repeatable performance across physical and digital stores. “Retail leaders don’t invest

Owkin Brings Biology Super Intelligence Closer to Reality with New AI Infrastructure for Biological Breakthroughs12.1.2026 18:00:00 CET | Press Release

Owkin, the AI company on a mission to solve the complexity of biology, today announced the launch of its agentic infrastructure for biology, making its best-in-class AI agents available to the healthcare ecosystem. The announcement comes at the JPM Healthcare Conference 2026 and follows Owkin’s recent strategic partnerships and its just-announced integration with Claude for Healthcare and Life Sciences by Anthropic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112461277/en/ Owkin, a 10-year-old AI company with $300 million in funding, is introducing the infrastructure, built on a unique advantage: unparalleled, curated, multimodal patient data from diverse geographies, collected from more than 800 hospitals over a decade. While other companies focus primarily on data derived from laboratory research, Owkin's patient data-trained AI agents enable comprehensive and clinically relevant insights that more accurately reflect

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye